Linked Life Data

16503852

Source:http://linkedlifedata.com/resource/pubmed/id/16503852

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2006-2-28
pubmed:abstractText
Multiple myeloma, for all practical purposes, remains an incurable malignancy; however, 5-year survival has improved substantially during the past 30 years. A major contribution to improved outcome is the use of high-dose chemotherapy and stem cell transplantation. This multifaceted approach to therapy requires an understanding of appropriate induction therapy, techniques for stem cell mobilization, appropriate conditioning and supportive care. Also of importance are prognosis, features that predict outcome, the suitability of transplant candidates, and post-transplantation maintenance therapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1744-8328
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
343-60
pubmed:dateRevised
2007-12-5
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
pubmed:affiliation
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA.
pubmed:publicationType
Journal Article, Review